Expected timeline to market If the TRIUMPH trials produce results consistent with Phase 2, regulatory submission could occur as early as late next year, with approval and market availability following twelve to eighteen months later
F&B takeaway: In the UK, private usage of GLP-1s is highest in the 30-39 age group, followed by 50 to 59, but declines after age 60 years
Many online peptides are mislabeled, underdosed, or contaminated
"A lot of people have reported that they were insulin-resistant and overweight, and that their periods were very irregular." "Thus, when we correct the insulin resistance with these medications, people start getting regular periods and start getting pregnant," she went on
Implementing targeted controls on GLP-1 coverage